The NMC has issued a public notice requesting all medical colleges and institutions to give feedback and raise objections to the draft rules within 30 days.  Julian Fernandez/pexels
India

National Medical Commission (NMC) Intervenes in the 2026 Draft Lab Animal Rules Debate

The 84-page draft framework aims to modernize laboratory ethics and enshrine the 3Rs, but the bureaucratic structure has sparked pushback; the National Medical Commission (NMC) intervenes

Author : Akanksha

Public reaction to Gazette Notification G.S.R. 864(E) has prompted intervention from the National Medical Commission. The NMC has issued a public notice requesting all medical colleges and institutions to give feedback and raise objections to the draft rules within 30 days. 

A major change to regulation in biological research is coming to India. The Ministry of Fisheries, Animal Husbandry, and Dairying has published a draft of updated rules for the prevention of cruelty to animals in experimentation, breeding, and trading. This 84-page document aims to replace current guidelines from 1968/98 and therefore modernise laboratory practice. However, it has quickly caused controversy. Due to the complex and restrictive rules, there is much debate surrounding these new regulations. 

Core Mandates of the 2026 Draft Animal Experimentation Rules

The 2026 rules aim to regulate the sourcing, breeding, housing, and experimentation of live vertebrate animals. These requirements apply to basic research, drug development, forensic work, and higher learning. 

Enshrining the 3Rs Principle: Replace, Reduce, and Refine 

All registered establishments are now required to implement the 3Rs. They must:

  • Replace live animals with alternative testing where possible. 

  • Reduce the number of animals used in experimentation to the lower numbers necessary to obtain valid results.

  • Refine breeding and experimental techniques to avoid causing pain. Humane endpoints and appropriate environmental enrichment must be implemented. 

Recent literature highlights that implementing the 3Rs into laboratory practice is not just ethically appropriate, but scientifically beneficial. Implementation of refinement reduces stress and therefore prevents bias in biochemical or histological data.

Also Read: India Embraces Global Collaboration to Eliminate Animal Models in New Drug Testing

Strict Prohibition on Wildlife, Strays, and Primates

The sourcing of certain animals is now heavily restricted. Stray and domestic animals cannot be used in experimentation unless it is an extreme emergency where serious harm may occur to people, animals, or the environment. Animals protected under the Wildlife (Protection) Amendment Act, 2022, or caught from the wild, cannot be used in experiments unless they have been given specific exemptions by relevant authorities. Non-human primates may only be used in experiments aimed at overcoming debilitating or life-threatening diseases in humans. Other species must be used if possible. If non-human primates are to be utilised, then it must be for a disease that cannot be investigated using any other species. 

Mandatory Four-Tier Severity Classification System

To standardise and control the amount of pain that animals undergo, all experimentation must be classified into one of four severities. Experiments must undergo a case-by-case analysis. 

Breakdown of the Experimental Severity Tiers

  • Non-Recovery: Procedures performed under general anaesthesia from which the animal does not recover. 

  • Mild: Observations, simple blood sampling, or non-invasive imaging (MRI). Minimal distress is caused to the animal, and overall wellbeing is unaffected. 

  • Moderate: Minor surgery or toxicity testing. Reversible effects occur, but cause short-term moderate or long-term mild pain. 

  • Severe: Major surgery, terminal endpoints, or application of Risk Group III/IV pathogens. These procedures are expected to cause prolonged severe pain and/or permanent disability. 

Establishments may not perform any severe, painful experiments in which pain is likely to be prolonged and cannot be reduced. The severity classification of ‘severe’ and ‘non-recovery’ in animals of a higher species than rodents or lagomorphs must be approved directly by the central Committee (CCSEA). Local Committees may no longer approve procedures of this severity in animals of higher species.  

Concerns are raised around delays in drug discovery and translation for high-severity experiments due to increased approval processes, requiring central approval from the CCSEA.

Overhaul of Institutional Governance and Bureaucracy 

Bureaucracy has increased greatly. All users, breeders, and traders must be issued a unique registration code, valid for 3 years. 

The New Nine-Member Institutional Animal Ethics Committee (IAEC)

Each institution must have a highly regulated 9-member Institutional Animal Ethics Committee (IAEC). An official quorum of 6 members must be achieved, including external members. To meet requirements, the committee must consist of:

  • A Biologist: 2 scientists from different fields, a veterinarian, and a scientist acting as head of the institution. 

  • A main and link nominee appointed by the CCSEA. 

  • An external Scientist and a socially aware nominee. 

Biannual Inspections and Mandatory Euthanasia Registers 

To ensure compliance, institutions in question must be inspected twice yearly by the main nominee and socially aware nominee. If an animal is placed under euthanasia, the following information must be recorded in a log. Information includes the chemical, quantity used, reason for euthanasia, and sign-off from both the investigating scientist and the nominated veterinarian. 

Also Read: Can 'Mini Brains' Replace Lab Animals? Organoids Are Changing How Scientists Study Disease

National Medical Commission Directs Institutions to File Objections

These new regulations have caused many objections from within the scientific community. Concerns are raised around delays in drug discovery and translation for high-severity experiments due to increased approval processes, requiring central approval from the CCSEA. 

However, the National Medical Commission (NMC) has responded to these concerns. In a notice sent out by Dr. Raghav Langer, all medical colleges and institutions under the authority of the NMC are encouraged to closely consider these rules and provide objections. 

Official Channels for Institutional Feedback and Objections

If academic/medical institutions wish to object to the increased bureaucracy, or suggest changes to the rules, they must do so in the following manner: 

  • Send to CCSEA: Provide comments/objections via email to cpcsea-mef [at] gov [dot] in or post them directly to the Member Secretary, Delhi Milk Scheme Complex within 30 days of the notification. 

  • Send to NMC: At the same time, send a copy of this submission to Prof. (Dr.) Mahendra Kumar Pant, Senior Advisor at NMC, by email to sr [dot] advisor [dot] ugmeb [at] nmc [dot] org [dot] in.

Balancing Ethical Research with Scientific Pragmatism

These 2026 draft rules mark a large step towards ethical research, prioritising animal welfare and the 3Rs. However, given the rapid growth in the pharmaceutical and medical industries in India, the high levels of bureaucracy in this legislation, particularly surrounding central approval and complex IAEC structures, may delay progress in research. With NMC encouraging medical institutions to raise objections, the final version of this legislation will depend on balancing ethical considerations with practicality in research. 

(Rh/APC)

ICMR-National Institute of Malaria Research Marks Golden Jubilee: 50 Years of Medical Research and Milestones

How Did a Chennai CA Allegedly Divert Rs 8.2 Crore from a Pharma Firm Through 95 Transactions and 44 Bank Accounts?

How Modern Sports Medicine Is Changing the Way Injuries Are Treated

A Healthier Home, A Healthier You: Rethinking Everyday Wellness

7 Best Risk Management Software Tools for Skilled Nursing Facilities